Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics


Nymox Pharmaceutical Corporation (NYMX): $2.02

-0.06 (-2.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NYMX POWR Grades


  • NYMX scores best on the Sentiment dimension, with a Sentiment rank ahead of 65.34% of US stocks.
  • NYMX's strongest trending metric is Momentum; it's been moving down over the last 44 weeks.
  • NYMX ranks lowest in Value; there it ranks in the 10th percentile.

NYMX Stock Summary

  • NYMX's price/sales ratio is 32,275.92; that's higher than the P/S ratio of 99.86% of US stocks.
  • With a year-over-year growth in debt of 189.8%, Nymox Pharmaceutical Corp's debt growth rate surpasses 95.24% of about US stocks.
  • As for revenue growth, note that NYMX's revenue has grown -97.77% over the past 12 months; that beats the revenue growth of merely 0.92% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Nymox Pharmaceutical Corp are INMB, MRSN, CVM, ZOM, and CALT.
  • NYMX's SEC filings can be seen here. And to visit Nymox Pharmaceutical Corp's official web site, go to www.nymox.com.

NYMX Valuation Summary

  • In comparison to the median Healthcare stock, NYMX's price/earnings ratio is 138.9% lower, now standing at -14.2.
  • Over the past 243 months, NYMX's EV/EBIT ratio has gone up 8.9.
  • NYMX's price/sales ratio has moved up 32812.5 over the prior 243 months.

Below are key valuation metrics over time for NYMX.

Stock Date P/S P/B P/E EV/EBIT
NYMX 2021-08-31 33220 77.4 -14.2 -13.9
NYMX 2021-08-30 33680 78.5 -14.3 -14.1
NYMX 2021-08-27 34140 79.6 -14.5 -14.3
NYMX 2021-08-26 33220 77.4 -14.2 -13.9
NYMX 2021-08-25 33520 78.1 -14.3 -14.1
NYMX 2021-08-24 32120 74.9 -13.7 -13.5

NYMX Growth Metrics

  • The 2 year price growth rate now stands at 15.23%.
  • Its 4 year revenue growth rate is now at -98.24%.
  • Its 2 year net cashflow from operations growth rate is now at -28.66%.
Over the past 37 months, NYMX's revenue has gone down $219,000.

The table below shows NYMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 0.005 -10.037 -11.738
2019-12-31 0.116 -7.43 -13.162
2018-12-31 0.299 -7.801 -10.594
2017-12-31 0.224 -6.206 -13.429
2017-12-31 0.224 -6.206 -13.429
2016-12-31 0.283611 -4.502167 -13.10961

NYMX Stock Price Chart Interactive Chart >

Price chart for NYMX

NYMX Price/Volume Stats

Current price $2.02 52-week high $3.50
Prev. close $2.08 52-week low $1.25
Day low $2.01 Volume 9,364
Day high $2.09 Avg. volume 294,583
50-day MA $1.84 Dividend yield N/A
200-day MA $2.10 Market Cap 166.41M

Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGH...

Benzinga | July 27, 2021

Who Has Been Buying Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

Yahoo | July 27, 2021

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: A...

Benzinga | July 15, 2021

The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) U...

Benzinga | July 14, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

InvestorPlace is starting the day off right by checking out the biggest pre-market stock movers, including the winners and losers.

William White on InvestorPlace | May 11, 2021

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo -7.76%
3-mo 27.85%
6-mo -18.55%
1-year -19.52%
3-year -17.89%
5-year -37.46%
YTD -18.55%
2020 12.73%
2019 67.94%
2018 -60.30%
2017 23.60%
2016 -18.60%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9731 seconds.